Enjoy complimentary customisation on priority with our Enterprise License!
It has been observed that the Prader-Willi-syndrome (PWS) is a disorder caused by the loss of active genes in a specific region of chromosome 15 and is characterized by the lack of feeling of fullness in people with PWS. The common symptoms of Prader-Willi-syndrome are hypotonia (poor muscle tone), hyperphagia (chronic overeating), mild to moderate intellectual impairment and learning disabilities, behavioral problems, and unusual fair skin and light-colored hair.
According to tests carried out by Fluorescence in situ hybridization (FISH), the cause of PWS has been identified to be the deleted genes in the chromosomes of the patients with PWS. Another testing method for PWS genetic testing is DNA methylation testing for the diagnosis of Prader-Willi-syndrome. As per the data published by the EMA based on the Committee for Orphan Medical Records (COMP), it is estimated that around 0.4 people in 10,000 people are affected by the symptoms of Prader-Willi-syndrome in the EU. Monotherapy is considered to be the most efficient approach for the treatment of Prader-Willi-syndrome as it uses a single drug to treat the disorder.
As per our pipeline analysis report, all of the drug molecules in the pipeline are being developed for the treatment of PWS. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Try a FREE sample of this report now!
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of prader-willi-syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
The oral route of administration (ROA) involves the administration of the drug molecules by placing them in the mouth cavity and in the subcutaneous method, the drug is delivered into the subcutis, which will have a more direct effect on the target cells.
According to this pipeline analysis report, all the molecules that are currently in the drug pipeline for PWS are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.